Search for…

• Antidromic strategies to target RASopathies

  B82137

  Antidromic strategies to target RASopathies

  • RAS detected at low levels on cell surface independent of the HLA complex
  • Targeting of extracellularly expressed RAS on cancer cells via bispecific T cell engager
  • Relevant for novel immunotherapies for RAS-driven malignancies
• Cytosolic RNA depletion by polymeric nanoparticles

  B83117

  Cytosolic RNA depletion by polymeric nanoparticles

  • Mucin nanoparticles cross-linked with anti-miRNA oligonucleotides
  • Treating systemic diseases associated with increased cellular RNA levels
  • Depletion of miRNA-21 reduced tumor growth in vivo by 50%
• The T-Cell-Therapy Success Code: Signatures of recent T-cell activation allow isolation of highly functional tumor-specific T cell receptors

  B81078

  The T-Cell-Therapy Success Code: Signatures of recent T-cell activation allow isolation of highly functional tumor-specific T cell receptors

  • Cost-effective isolation of highly functional tumor-specific TCRs
  • Method using predictive markers to identify TCRs of high functional quality
  • Isolation of TCRs from easily accessible peripheral blood
• New cell therapy cures metastatic cancer in mouse

  B81137

  New cell therapy cures metastatic cancer in mouse

  • New RESURRECT NK and T cell therapy cures metastatic cancer in mouse
  • RESURRECT T and NK cells overcome immunosuppression in tumors and metastases
  • RESURRECT cells are effective in tumors resistant to standard immunotherapies
• Liposome-encapsidated bioactive hexapeptides for targeted pancreatic cancer therap

  B80078

  Liposome-encapsidated bioactive hexapeptides for targeted pancreatic cancer therap

  • Targeted tumor therapy for highly aggressive pancreatic cancers
  • Particularly suited for combinational therapy
  • Targeted therapies for human solid tumors bearing wild-type TP53

5 of 96 Tech Offers